Navigation Links
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Date:10/17/2011

tock issuable upon conversion of the notes, nor shall there be any offer, solicitation or sale of any securities, including any notes or any shares of the Company's common stock issuable upon conversion of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Regeneron Pharmaceuticals, Inc.Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"), which include, among other things, those concerning whether or not the Company will offer the notes or consummate the proposed offering, the final terms of the notes and the proposed offering, prevailing market conditions, the anticipated principal amount of the notes and the anticipated use of the proceeds of the proposed offering.  The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Act.  Forward-looking statements may be ident
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
6. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
10. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)...  The Myeloma Crowd Research Initiative (MCRI) completed ... proposals that will now be evaluated for further ... validated funding initiative uncovering solutions for high-risk multiple ... MCRI included preliminary vetting by the Scientific Advisory ... of innovative projects focusing on high-risk myeloma, we ...
(Date:3/31/2015)... Cleveland, OH (PRWEB) March 31, 2015 ... from its licensor, SDG, Inc., that a United States ... for liver-targeted insulin therapy. , Entitled “Lipid ... patent covers composition of matter claims related to the ... a system for enabling injected insulin to more effectively ...
(Date:3/30/2015)... , March 30, 2015  Heidrick & Struggles (Nasdaq: ... leadership consulting and culture shaping worldwide, ... firm to lead its global Healthcare and Life Sciences practice. ... Life Sciences, Mitchell will lead a team of more than ... Europe and Asia serving ...
(Date:3/30/2015)... March 30, 2015 /CNW/ - A new national Labour ... salaries and demographic profiles of new graduates entering the ... – Building Careers for New Grads in Biotech," is ... Research-Based Pharmaceutical Companies (Rx&D) and features data collected from ... wage subsidy program from 2013 to 2015. ...
Breaking Biology Technology:Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4
... Readies R & D facilities for Ap3ana, CTI,s ... Cell Therapeutics, Inc. (CTI),(Nasdaq: CTIC ) announced ... President and COO of a Tyr Pharma and ... the Novartis Research,Foundation, has been named President of ...
... BioPharma,Corp. (TSX; FSE: HBP) today announced that it has ... 6,800,000 units at $1.68 per,unit, for gross proceeds totaling ... and one-half of one common share,purchase warrant, with each ... subject to adjustment, one common share at a price,of ...
... Investors, WILMINGTON, Del., Oct. 2 Speaking ... General Manager John Ranieri,said the company,s plans to ... on track and making significant technical progress toward ... feedstocks,economically into biofuels., "Biobutanol and cellulosic ethanol ...
Cached Biology Technology:Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4Helix Biopharma Closes $11.4 Million Private Placement 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
(Date:3/2/2015)... Lithuania , March 2, 2015   Neurotechnology ... technologies, today introduced the SentiGaze Software Development Kit ... to create applications that use off-the-shelf webcams to track ... user gazes at a monitor. Heatmaps can be used ... the effectiveness of online advertising. The SDK can also ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... obesity increasing, school administrators and public health officials are ... a study published in the November/December 2008 issue of ... researchers found that reduction or elimination of SSB from ... adolescents. Working with four schools in Maine ...
... to be averted, atmospheric carbon dioxide (CO2) must be reduced below ... in Open Atmospheric Science Journal by a ... and France. The authors, who include two Yale ... which civilization developed, an optimum CO2 level would be less than ...
... Ph.D., of the New York City Department of Health and ... be one of our body,s main protections against damage from ... of Low Radiation , Hayes explains that calcitriol, the active ... and could be used as a safe protective agent before ...
Cached Biology News:Revised theory suggests carbon dioxide levels already in danger zone 2Could vitamin D save us from radiation? 2
...
Auto/Zyme Reagent...
HistoScan HRP Kit Universal Goat Kit...
Interact with both DNA and RNA; fluorescence green (Em=525 nm) bound to DNA; and fluorescence red (Em=~650 nm) bound to RNA....
Biology Products: